Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats

In Vivo

Volumn 22, Issue 6, 2008, Pages 693-698

  Chang, Chih Hsien ^a   Chou, Ta Kai ^a   Yang, Chi Yu ^b   Chang, Tsui Jung ^a   Wu, Yu Hsien ^a   Lee, Te Wei ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^b ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

Author keywords

Biodistribution; Pharmacokinetics; Pig; Radiolabeled; Recombinant human factor IX (rhFIX)

Indexed keywords

IODINE 131; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BONE TISSUE; BRAIN TISSUE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG UPTAKE; HEART; ISOTOPE LABELING; KIDNEY PARENCHYMA; LARGE INTESTINE; LIVER; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE TISSUE; NONHUMAN; RADIOACTIVITY; RAT; SMALL INTESTINE; SPLEEN; SPRAGUE DAWLEY RAT; STOMACH; TESTIS; TRANSGENIC PIG;

EID: 57849167945     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Giangrande P: Haemophilia B: Christmas disease. Expert Opin Pharmacother 6: 1517-1524, 2005.
2. Chang HH, Yang YL, Hung MH, Tsay W and Shen MC: Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. J Formos Med Assoc 106: 281-287, 2007.
3. Kaufman RJ, Wasley LC, Furie BC, Furie B and Shoemaker CB: Expression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 261: 9622-9628, 1986.
4. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G and Schwartz BA: Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 42: 190-197, 2002.
5. White G, Shapiro A, Ragni M, Garzone P, Goodfellow J, Tubridy K and Courter S: Clinical evaluation of recombinant factor IX. Semin Hematol 35: 33-38, 1998.
6. Bond M, Jankowski M, Patel H, Karnik S, Strang A, Xu B, Rouse J, Koza S, Letwin B, Steckert J, Amphlett G and Scoble H: Biochemical characterization of recombinant factor IX. Semin Hematol 35: 11-17, 1998.
7. Bush L, Webb C, Bartlett L and Burnett B: The formulation of recombinant factor IX: stability, robustness, and convenience. Semin Hematol 35: 18-21, 1998.
8. Adamson S, Charlebois T, O'Connell B and Foster W: Viral safety of recombinant factor IX. Semin Hematol 35: 22-27, 1998.
9. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S and Roberts HR: Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55: 638-648, 1994.
10. Hammer RE, Pursel VG, Rexroad CE Jr, Wall RJ, Bolt DJ, Ebert KM, Palmiter RD and Brinster RL: Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315: 680-683, 1985.
11. Melo EO, Canavessi AM, Franco MM and Rumpf R: Animal transgenesis: state of the art and applications. J Appl Genet 48: 47-61, 2007.
12. Lunney JK: Advances in swine biomedical model genomics. Int J Biol Sci 3: 179-184, 2007.
13. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A and Campbell KH: Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 278: 2130-2133, 1997.
14. Wu SC, Cheng TK, Chen CM, Lin SP, Yen CH and Yang PC: Method for expressing multiple recombinant proteins in milk of transgenic non-human mammals. USA patent number 7087808, 2006.
15. Keith JC Jr, Ferranti TJ, Misra B, Frederick T, Rup B, McCarthy K, Faulkner R, Bush L and Schaub RG: Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 73: 101-105, 1995.
16. Chang CH, Hsu WC, Wang CY, Jan ML, Tsai TH, Lee TW, Lynn SG, Yeh CH and Chang TJ: Longitudinal microSPECT/CT imaging and pharmacokinetics of synthetic luteinizing hormone-releasing hormone (LHRH) vaccine in rats. Anticancer Res 27: 3251-3258, 2007.
17. 125I-interferons in pharmacokinetic and tissue distribution studies. J Interferon Res 4: 493-498, 1984.
18. Zurbriggen R, Metcalfe IC, Gluck R, Viret JF and Moser C: Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines 2: 295-304, 2003.
19. Macklis RM: Iodine-131 tositumomab (Bexxar) in a radiation oncology environment. Int J Radiat Oncol Biol Phys 66: S30-34, 2006.
20. Morfini M: Pharmacokinetics of factor VIII and factor IX. Haemophilia 9(Suppl 1): 94-99, 2003.
21. Berntorp E and Bjorkman S: The pharmacokinetics of clotting factor therapy. Haemophilia 9: 353-359, 2003.
22. Yen CH and Lin ML: Method of separating protein from animal milk. 2007: USA patent number 7214319.
23. Fuchs HE, Trapp HG, Griffith MJ, Roberts HR and Pizzo SV: Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 73: 1696-1703, 1984.
24. Salacinski PR, McLean C, Sykes JE, Clement-Jones VV and Lowry PJ: Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 117: 136-146, 1981.
25. Reilly RM, Chen P, Wang J, Scollard D, Cameron R and Vallis KA: Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 47: 1023-1031, 2006.
26. Behr TM, Goldenberg DM and Becker WS: Radioimmunotherapy of solid tumors: a review "of mice and men". Hybridoma 16: 101-107, 1997.
27. Lee M, Morfini M, Negrier C and Chamouard V: The pharmacokinetics of coagulation factors. Haemophilia 12(Suppl 3): 1-7, 2006.